Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”), an innovation-driven global life sciences company and Guardant Health, a leading precision oncology company, have signed a co-marketing agreement to jointly promote the Guardant360^® portfolio of liquid and tissue biopsy tests across India and Nepal. The tests to be promoted include the Guardant360® and Guardant360 TissueNext™ tests for comprehensive genomic profiling and the Guardant360 Response™ test for monitoring response to treatment.

The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region. By combining resources and expertise, both organisations aim to empower oncologists with the necessary tools to help inform treatment decisions for patients with advanced cancer.

“Cancer is a major public health problem in India and Nepal, with one out of nine Indians likely to develop cancer in his or her lifetime and more than 20,000 people in Nepal diagnosed with cancer every year,” said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East and Africa.^1,2 “This collaboration with Zydus to co-promote the Guardant360 portfolio across their extensive network signifies our mutual commitment to address unmet cancer treatment needs by equipping oncologists with genomic tests that help patients with advanced cancers receive the best targeted treatment option in order to improve outcomes.”

Speaking on the development, a spokesperson from Zydus Lifesciences Limited said, “We have always believed in bringing together science, innovation and nurturance for a more patient centric approach in healthcare. This collaboration with Guardant Health helps us offer all of this for patients suffering from advanced forms of cancer. Access to these critical diagnostic tests and precision oncology will go a long way in guiding better clinical outcomes and support the fight against advanced solid cancer.”

For doctors treating patients with advanced cancer, the Guardant360 portfolio of tests provides a complete tumour genomic view at every step of the treatment journey, offering insights to

help them quickly start patients on the optimal treatment based on their tumour genomic profile, and to monitor response to that treatment.

Guardant360 is a minimally invasive liquid biopsy test that provides comprehensive genomic profiling (CGP) of all solid tumours by analysing circulating tumour DNA (ctDNA) from a simple blood draw. Guardant360 TissueNext provides CGP results from a tumour tissue biopsy to give doctors actionable information when tissue testing is appropriate. Guardant360 Response is a monitoring test that allows oncologists to track a patient's treatment response over time.

***

About Zydus Lifesciences Limited

Zydus Lifesciences Limited with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs nearly 25,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Zydus is one of the leading players in the Oncology segment in India and has been at the forefront launching several First- in-India biosimilars and therapies. With a highly specialized and patient centric approach, the company has been able to bring access and affordability in cancer therapies. Six of the eight oncology pillar brands are leaders in their respective categories. For more details visit www.zyduslife.com and follow the company on LinkedIn and Twitter.

About Guardant Health AMEA

Guardant Health AMEA is a wholly owned subsidiary of Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and potentially lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360^®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and Guardant INFINITY™ for patients with advanced-stage cancer, and Guardant Reveal™ for patients with early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, For more information, visit guardanthealthamea.com and follow the company on LinkedIn, Twitter and Facebook.

References

1. Sathishkumar, K., Chaturvedi, M., Das, P., Stephen, S., & Mathur, P. (2022). Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. The Indian journal of medical research, 156(4&5), 598–607. https://doi.org/10.4103/ijmr.ijmr_1821_22
2. Shrestha R, Shrestha G, Paneru P. Asian Pac J Cancer Care,8 (2), 275-279

Zydus Lifesciences Ltd.

Media:

Sujatha Rajesh sujatha.rajesh@zyduslife.com

Guardant Health

Investors:

investors@guardanthealth.com

Media:

Jasmeet (Jasmine) Kaur press_amea@guardanthealth.com

Prakash Raja press_amea@guardanthealth.com

Source:- Zydus Life Science